CD74–ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non‐small cell lung cancer cells

The treatment of non‐small cell lung cancer (NSCLC) patients harboring a proto‐oncogene tyrosine‐protein kinase c‐ros oncogene 1 (ROS1) fusion gene has greatly benefited from the use of crizotinib. However, drug resistance inevitably occurs after 1 year of treatment. Clinical studies have shown that...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The FEBS journal 2024-03, Vol.291 (6), p.1199-1219
Hauptverfasser:	Xu, Xiaobo, Li, Ye, Xu, Rui, Meng, Yuting, Li, Zengqiang, Zuo, Daiying, Wu, Yingliang
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis Autophagy CD74‐ROS1 L2026M crizotinib resistance Drug resistance Extracellular signal-regulated kinase Fusion protein Homology Inhibitors invasion Kinases Lung cancer MEK inhibitors MEK/ERK Metabolic pathways Metastases Metastasis migration Mutants Mutation Non-small cell lung carcinoma Oncogenes Patients Polymerase chain reaction Protein kinase C Rapamycin Small cell lung carcinoma Staining Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!